<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; NLEM</title>
	<atom:link href="http://www.tapanray.in/tag/nlem/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>On Serious Healthcare, Some Bizarre Decisions</title>
		<link>http://www.tapanray.in/on-serious-healthcare-some-bizarre-decisions/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=on-serious-healthcare-some-bizarre-decisions</link>
		<comments>http://www.tapanray.in/on-serious-healthcare-some-bizarre-decisions/#comments</comments>
		<pubDate>Mon, 15 Aug 2016 00:00:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA["Search Medicine Price"]]></category>
		<category><![CDATA['Pharma Jan Samadhan']]></category>
		<category><![CDATA[65%]]></category>
		<category><![CDATA[65(11)(c)]]></category>
		<category><![CDATA[Acts]]></category>
		<category><![CDATA[app]]></category>
		<category><![CDATA[Aushadhi]]></category>
		<category><![CDATA[bizarre]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[cosmetics]]></category>
		<category><![CDATA[decision]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Jan]]></category>
		<category><![CDATA[Mantri]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[original. substitution]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rules]]></category>
		<category><![CDATA[Samadhan]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[search]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Yojana’]]></category>
		<category><![CDATA[‘Pradhan]]></category>
		<category><![CDATA[‘Pradhan Mantri Jan-Aushadhi Yojana"]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7773</guid>
		<description><![CDATA[On August 04, 2016, it was widely reported by the media that the Union Minister of Chemicals and Fertilizers &#8211; Mr. Anant Kumar, would launch a new digital initiative of the National Pharmaceutical Pricing Authority (NPPA), named, &#8220;Search Medicine Price&#8221;, &#8230; <a href="http://www.tapanray.in/on-serious-healthcare-some-bizarre-decisions/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/on-serious-healthcare-some-bizarre-decisions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>NCDs: Any Wolf Around, In Sheep’s Clothing? </title>
		<link>http://www.tapanray.in/ncds-any-wolf-around-in-sheeps-clothing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ncds-any-wolf-around-in-sheeps-clothing</link>
		<comments>http://www.tapanray.in/ncds-any-wolf-around-in-sheeps-clothing/#comments</comments>
		<pubDate>Mon, 08 Aug 2016 00:00:40 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[clothing]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[Modern]]></category>
		<category><![CDATA[NCD]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Playbook]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sheep's]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Wolf]]></category>
		<category><![CDATA[Wolf in sheep's clothing]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7766</guid>
		<description><![CDATA[Noncommunicable Diseases (NCDs), such as, cancer, cardiovascular disease, diabetes and chronic respiratory disease, are now the leading cause of death in the world, accounting for 63 percent of annual deaths. Over 80 percent of NCDs occur in lower or middle &#8230; <a href="http://www.tapanray.in/ncds-any-wolf-around-in-sheeps-clothing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ncds-any-wolf-around-in-sheeps-clothing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drugs &amp; Devices: Chasing Never-Enough Profit And Price Control</title>
		<link>http://www.tapanray.in/drugs-devices-chasing-never-enough-profit-and-price-control/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drugs-devices-chasing-never-enough-profit-and-price-control</link>
		<comments>http://www.tapanray.in/drugs-devices-chasing-never-enough-profit-and-price-control/#comments</comments>
		<pubDate>Mon, 25 Jul 2016 00:00:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIIMS]]></category>
		<category><![CDATA[angioplasty]]></category>
		<category><![CDATA[CAD]]></category>
		<category><![CDATA[Cardio]]></category>
		<category><![CDATA[Chasing]]></category>
		<category><![CDATA[coronary]]></category>
		<category><![CDATA[CVD]]></category>
		<category><![CDATA[DES]]></category>
		<category><![CDATA[Devices]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[driven]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[never-enough-pr0fit]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[stent]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[vascular]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7732</guid>
		<description><![CDATA[On July 20, 2016, the Union Ministry of Health of India announced the addition of Coronary Stents to the National List of Essential Medicines (NLEM) 2015 with immediate effect, bringing them under the Drug Price Control Order. Reacting sharply to &#8230; <a href="http://www.tapanray.in/drugs-devices-chasing-never-enough-profit-and-price-control/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drugs-devices-chasing-never-enough-profit-and-price-control/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Arbitrary Pricing of Essential Drugs Invites State Intervention</title>
		<link>http://www.tapanray.in/arbitrary-pricing-of-essential-drugs-invites-state-intervention/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=arbitrary-pricing-of-essential-drugs-invites-state-intervention</link>
		<comments>http://www.tapanray.in/arbitrary-pricing-of-essential-drugs-invites-state-intervention/#comments</comments>
		<pubDate>Mon, 23 May 2016 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[arbitrary]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[Combiflam]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[premium]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[winner]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7644</guid>
		<description><![CDATA[Arbitrary drug pricing has now become a subject of a raging debate, all over the globe. It involves both patented and generic drugs, as we have recently witnessed in the largest pharma market in the world – the United States. &#8230; <a href="http://www.tapanray.in/arbitrary-pricing-of-essential-drugs-invites-state-intervention/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/arbitrary-pricing-of-essential-drugs-invites-state-intervention/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Drug Price Control The Key Growth Barrier For Indian Pharma Industry?</title>
		<link>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry</link>
		<comments>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/#comments</comments>
		<pubDate>Mon, 19 Oct 2015 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1995]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[AIOCD-AWACS]]></category>
		<category><![CDATA[apex]]></category>
		<category><![CDATA[Atorvastatin]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[corollary]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Crocin Advance]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[health care UHC]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hikes]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[increases]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[key]]></category>
		<category><![CDATA[Maharashtra]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Para 19]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[safeguard]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Universal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7183</guid>
		<description><![CDATA[The corollary of the above headline could well be: “Are drug price hikes the key growth driver for the Indian Pharmaceutical Market (IPM)?” Whenever the first question, as appears in the headline of this article: “Is drug price control a &#8230; <a href="http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Price Control in India: A Fresh Advocacy With Blunt Edges</title>
		<link>http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges</link>
		<comments>http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/#comments</comments>
		<pubDate>Mon, 07 Sep 2015 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[Authority]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[blunt]]></category>
		<category><![CDATA[campaign]]></category>
		<category><![CDATA[capita]]></category>
		<category><![CDATA[cheapest]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[cutting]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[edges]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[income]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Make in India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[Para 19]]></category>
		<category><![CDATA[parity]]></category>
		<category><![CDATA[per]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pharmasofttech]]></category>
		<category><![CDATA[power]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[purchasing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Subburaj]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Yeh dil maange more]]></category>
		<category><![CDATA[“Assessing the Impact of Price Control Measures on Access to Medicines in India”]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7017</guid>
		<description><![CDATA[It is no-brainer that the advocacy initiatives to influence the new Government doing away with the ‘Drug Price Control’ in India has re-started by flooring the gas pedal. A fresh invigorating effort, apparently a pretty expensive one, has been initiated &#8230; <a href="http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India’s Drug Pricing Policy: “Absurd, Unreasonable And Irrational&#8221; – Supreme Court</title>
		<link>http://www.tapanray.in/indias-drug-pricing-policy-absurd-unreasonable-and-irrational-supreme-court/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-drug-pricing-policy-absurd-unreasonable-and-irrational-supreme-court</link>
		<comments>http://www.tapanray.in/indias-drug-pricing-policy-absurd-unreasonable-and-irrational-supreme-court/#comments</comments>
		<pubDate>Mon, 20 Jul 2015 00:00:36 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1996]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[Achhe din]]></category>
		<category><![CDATA[All India Drug Action Network]]></category>
		<category><![CDATA[Bank]]></category>
		<category><![CDATA[coat-based drug pricing]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[irrational]]></category>
		<category><![CDATA[JSA]]></category>
		<category><![CDATA[lawmakers]]></category>
		<category><![CDATA[Market Based Drug-Pricing]]></category>
		<category><![CDATA[NGO]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Policy. Absurd]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Supreme Court]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Unreasonable]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6830</guid>
		<description><![CDATA[On July 15, 2015, while hearing a petition related to the current &#8216;Market Based Drug-Pricing Policy&#8217; of the country, the Supreme Court of India expressed its bewilderment on the very rationality of the ‘National Pharmaceutical Pricing Policy 2012’ and directed the &#8230; <a href="http://www.tapanray.in/indias-drug-pricing-policy-absurd-unreasonable-and-irrational-supreme-court/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-drug-pricing-policy-absurd-unreasonable-and-irrational-supreme-court/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India To Expand NLEM 2011: A Step In The Right Direction</title>
		<link>http://www.tapanray.in/india-to-expand-nlem-2011-a-step-in-the-right-direction/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-to-expand-nlem-2011-a-step-in-the-right-direction</link>
		<comments>http://www.tapanray.in/india-to-expand-nlem-2011-a-step-in-the-right-direction/#comments</comments>
		<pubDate>Mon, 11 May 2015 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1995]]></category>
		<category><![CDATA[2002]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[2014-15]]></category>
		<category><![CDATA[2015-16]]></category>
		<category><![CDATA[Ananth Kumar]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[direction]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[expand]]></category>
		<category><![CDATA[Expansion]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Katoch]]></category>
		<category><![CDATA[List]]></category>
		<category><![CDATA[Lok Sabha]]></category>
		<category><![CDATA[Margaret Chan]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PHFI]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[public health foundation]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reuters]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[STG]]></category>
		<category><![CDATA[Supreme Court]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[union budget]]></category>
		<category><![CDATA[W.H.O]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6591</guid>
		<description><![CDATA[Responding to growing discontentment on the flawed National List of Essential Medicines 2011 (NLEM 2011) and equally vociferous demand for its urgent rectification, on May 5, 2015, in a written reply to the Lower House of Indian Parliament (Lok Sabha) &#8230; <a href="http://www.tapanray.in/india-to-expand-nlem-2011-a-step-in-the-right-direction/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-to-expand-nlem-2011-a-step-in-the-right-direction/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does ‘Free-Market Economy’ Work For Branded Generic Drugs In India?</title>
		<link>http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-free-market-economy-work-for-branded-generic-drugs-in-india</link>
		<comments>http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/#comments</comments>
		<pubDate>Mon, 27 Apr 2015 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[Badm Medicine]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[chemicals]]></category>
		<category><![CDATA[chemicals. and. fertilizers]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[Delhi School of Economics]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DoP. department of pharmaceuticals]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DSE]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Editorial]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[Fertilizers]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[Free Market Economy]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[IJME]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Make]]></category>
		<category><![CDATA[Make in India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[paradox]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[‘Dorfman-Steiner’]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6557</guid>
		<description><![CDATA[On April 20, 2015, a panel of 31 lawmakers of the Standing Committee on Chemicals and Fertilizers tabled its report in the Indian Parliament. The committee emphasized that patients in India should have access to all medicines, including life saving drugs, &#8230; <a href="http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma &amp; Healthcare: Where The Healers Turn Looters?</title>
		<link>http://www.tapanray.in/pharma-healthcare-where-the-healers-turn-looters/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-healthcare-where-the-healers-turn-looters</link>
		<comments>http://www.tapanray.in/pharma-healthcare-where-the-healers-turn-looters/#comments</comments>
		<pubDate>Mon, 24 Nov 2014 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[300 doctors]]></category>
		<category><![CDATA[Ahmedabad]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[clothing]]></category>
		<category><![CDATA[DNA]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[healers]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[looters]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[memorial]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Octreotide]]></category>
		<category><![CDATA[Octride]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sandostatin]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[sheep]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tata]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[Wolf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6221</guid>
		<description><![CDATA[Two news reports of the last week, though no longer shocking, made me think exactly the same way as the headline of this article epitomizes. These reports are not just two isolated instances, but an integral part of a similar &#8230; <a href="http://www.tapanray.in/pharma-healthcare-where-the-healers-turn-looters/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-healthcare-where-the-healers-turn-looters/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
